HIV vaccine - Epimmune

Drug Profile

HIV vaccine - Epimmune

Alternative Names: CY 2301; HIV vaccine - Cytel

Latest Information Update: 16 Aug 2002

Price : $50

At a glance

  • Originator Epimmune
  • Class AIDS vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued HIV infections

Most Recent Events

  • 15 Jul 1999 Epimmune has been awarded a US patent covering its epitope-based vaccine technology
  • 31 Dec 1997 Discontinued - Phase-II for HIV infections treatment in USA (unspecified route)
  • 28 Aug 1997 Phase-II clinical trials for HIV infections treatment in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top